{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:25Z","timestamp":1786119325051,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/jcp.0b013e3181bf6303","type":"journal-article","created":{"date-parts":[[2009,11,7]],"date-time":"2009-11-07T03:15:39Z","timestamp":1257563739000},"page":"561-564","source":"Crossref","is-referenced-by-count":23,"title":["A Randomized Controlled Trial of Atomoxetine in Generalized Social Anxiety Disorder"],"prefix":"10.1097","volume":"29","author":[{"given":"Lakshmi N.","family":"Ravindran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Letamendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.publhealth.29.020907.090847","article-title":"The descriptive epidemiology of commonly occurring mental disorders in the United States.","volume":"29","author":"Kessler","year":"2008","journal-title":"Annu Rev Public Health"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/14737175.8.2.235","article-title":"Pharmacotherapy for social anxiety disorder: a systematic review.","volume":"8","author":"Ipser","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004714-199804000-00005","article-title":"Imipramine in the treatment of social phobia.","volume":"18","author":"Simpson","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","article-title":"Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.","volume":"19","author":"Allgulander","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","article-title":"A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.","volume":"66","author":"Liebowitz","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","article-title":"Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.","volume":"62","author":"Liebowitz","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-199907000-00006","article-title":"Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders.","volume":"14","author":"Altamura","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.jcp.0000085419.74359.a4","article-title":"An open clinical trial of reboxetine in the treatment of social phobia.","volume":"23","author":"Atmaca","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/01.chi.0000169012.81536.38","article-title":"Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.","volume":"44","author":"Kratochvil","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/chi.0b013e3180ca8385","article-title":"Atomoxetine treatment for pediatric patients with attention-deficit\/hyperactivity disorder with comorbid anxiety disorder.","volume":"46","author":"Geller","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/da.20549","article-title":"Atomoxetine treatment in adults with attention-deficit\/hyperactivity disorder and comorbid social anxiety disorder.","volume":"26","author":"Adler","year":"2009","journal-title":"Depress Anxiety"},{"issue":"suppl 20","key":"R13-8-20210128","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S0033291798007879","article-title":"Psychometric properties of the Liebowitz Social Anxiety Scale.","volume":"29","author":"Heimberg","year":"1999","journal-title":"Psychol Med"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"suppl 3","key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability.","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","article-title":"Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.","volume":"177","author":"Stein","year":"2005","journal-title":"Psychopharmacology"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/026988110101500314","article-title":"The placebo response in social phobia.","volume":"15","author":"Oosterbaan","year":"2001","journal-title":"J Psychopharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-200912000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:21Z","timestamp":1786039401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200912000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181bf6303","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}